« Previous
Next »
Titles
- S12 nonclinical biodistribution considerations for gene therapy products: guidance for industry1
- S1B(R1) addendum to S1B testing for carcinogenicity of pharmaceuticals: guidance for industry1
- SAMHSA is missing opportunities to better monitor access to medication-assisted treatment through the buprenorphine waiver program1
- Safe at home?: Developing effective criminal background checks and other screening policies for home care workers1
- Science & tech spotlight: vaccine safety1
- Science and tech spotlight: CRISPR gene editing1
- Scientific integrity: HHS agencies need to develop procedures and train staff on reporting and addressing political interference : report to congressional addressees1
- Scientific integrity: HHS agencies need to develop procedures and train staff on reporting and addressing political interference : testimony before the Select Subcommittee on the Coronavirus Crisis, Committee on Oversight and Reform, House of Representatives1
- Selected health care coalitions increased involvement in whole community preparedness but face developmental challenges following new requirements in 20171
- Short-term, limited-duration insurance and risks to California's insurance market1
- Size, shape, and other physical attributes of generic tablets and capsules: guidance for industry1
- Smoking cessation and related indications: developing nicotine replacement therapy drug products : guidance for industry1
- Social Security Administration: Actions needed by SSA to ensure disability medical consultants are properly screened and trained : report to the Committee on Ways and Means, Subcommittee on Social Security, House of Representatives1
- Social Security disability: action needed to help agency staff understand and follow policies related to prescription opioid misuse : report to the Subcommittee on Social Security, Committee on Ways and Means, House of Representatives1
- Soft (hydrophilic) daily wear contact lenses: performance criteria for safety and performance based pathway : guidance for industry and Food and Drug Administration staff1
- Some Medicare Advantage Organization denials of prior authorization requests raise concerns about beneficiary access to medically necessary care1
- Some Medicare Advantage companies leveraged chart reviews and health risk assessments to disproportionately drive payments1
- Some manufacturers reported inaccurate drug product data to CMS1
- Some nursing homes' reported staffing levels in 2018 raise concerns: consumer transparency could be increased1
- Some skin substitute manufacturers did not comply with new ASP reporting requirements1